Warning! GuruFocus detected
3 Severe warning signs
with PHM.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Pharma Mar SA
ISIN : ES0169501022
Compare
Compare
Traded in other countries / regions
PHM.SpainPHMMF.USA0RC6.UKPHM.AustriaPMRA.GermanyPHM1.Mexico Index Membership
IBEX 35 IPO Date
2000-09-08Description
Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and markets insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.03 | |||||
| Equity-to-Asset | 0.6 | |||||
| Debt-to-Equity | 0.25 | |||||
| Debt-to-EBITDA | 2.41 | |||||
| Interest Coverage | 2.55 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 8.51 | |||||
| Beneish M-Score | -1.92 | |||||
| WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -7.8 | |||||
| 3-Year EBITDA Growth Rate | -40.6 | |||||
| 3-Year EPS without NRI Growth Rate | -33.9 | |||||
| 3-Year Book Growth Rate | 6.3 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 34.49 | |||||
| 9-Day RSI | 39.46 | |||||
| 14-Day RSI | 43.66 | |||||
| 3-1 Month Momentum % | 25.1 | |||||
| 6-1 Month Momentum % | 106.22 | |||||
| 12-1 Month Momentum % | 240.74 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.03 | |||||
| Quick Ratio | 2.41 | |||||
| Cash Ratio | 1.87 | |||||
| Days Inventory | 2039.87 | |||||
| Days Sales Outstanding | 63.42 | |||||
| Days Payable | 1520.78 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.73 | |||||
| Dividend Payout Ratio | 0.44 | |||||
| 3-Year Dividend Growth Rate | 2.7 | |||||
| Forward Dividend Yield % | 0.73 | |||||
| 5-Year Yield-on-Cost % | 0.73 | |||||
| 3-Year Average Share Buyback Ratio | 0.8 | |||||
| Shareholder Yield % | 0.79 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 95.32 | |||||
| Operating Margin % | 3.6 | |||||
| Net Margin % | 14.94 | |||||
| FCF Margin % | -5.42 | |||||
| ROE % | 13.63 | |||||
| ROA % | 7.8 | |||||
| ROIC % | 9.08 | |||||
| 3-Year ROIIC % | -531.71 | |||||
| ROC (Joel Greenblatt) % | 21.61 | |||||
| ROCE % | 5.89 | |||||
| Years of Profitability over Past 10-Year | 6 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 59.5 | |||||
| PE Ratio without NRI | 59.86 | |||||
| Shiller PE Ratio | 58.85 | |||||
| PS Ratio | 8.87 | |||||
| PB Ratio | 7.48 | |||||
| Price-to-Tangible-Book | 7.51 | |||||
| Price-to-Operating-Cash-Flow | 256.21 | |||||
| EV-to-EBIT | 99 | |||||
| EV-to-EBITDA | 67.42 | |||||
| EV-to-Revenue | 8.19 | |||||
| EV-to-FCF | -153.55 | |||||
| Price-to-GF-Value | 2.06 | |||||
| Price-to-Projected-FCF | 2.51 | |||||
| Price-to-Median-PS-Value | 2.02 | |||||
| Price-to-Graham-Number | 4.47 | |||||
| Price-to-Net-Current-Asset-Value | 14.3 | |||||
| Price-to-Net-Cash | 118.2 | |||||
| Earnings Yield (Greenblatt) % | 1.01 | |||||
| FCF Yield % | -0.62 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Pharma Mar SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 174.855 | ||
| EPS (TTM) (€) | 1.49 | ||
| Beta | 0.84 | ||
| 3-Year Sharpe Ratio | 0.55 | ||
| 3-Year Sortino Ratio | 1.02 | ||
| Volatility % | 51.37 | ||
| 14-Day RSI | 43.66 | ||
| 14-Day ATR (€) | 3.607028 | ||
| 20-Day SMA (€) | 92.9825 | ||
| 12-1 Month Momentum % | 240.74 | ||
| 52-Week Range (€) | 26.16 - 105.8 | ||
| Shares Outstanding (Mil) | 17.31 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Pharma Mar SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Pharma Mar SA Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Pharma Mar SA Frequently Asked Questions
What is Pharma Mar SA(XMAD:PHM)'s stock price today?
The current price of XMAD:PHM is €88.65. The 52 week high of XMAD:PHM is €105.80 and 52 week low is €26.16.
When is next earnings date of Pharma Mar SA(XMAD:PHM)?
The next earnings date of Pharma Mar SA(XMAD:PHM) is 2025-04-23 Est..
Does Pharma Mar SA(XMAD:PHM) pay dividends? If so, how much?
The Dividend Yield %  of Pharma Mar SA(XMAD:PHM) is 0.73% (As of Today), Highest Dividend Payout Ratio of Pharma Mar SA(XMAD:PHM) was 13.54. The lowest was 0.06. And the median was 0.23. The  Forward Dividend Yield % of Pharma Mar SA(XMAD:PHM) is 0.73%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers